The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The current role and uncertain future of autoSCT in Hodgkin lymphoma
Carlos Almeida Ramos, MD, PhD, Baylor College of Medicine, Houston, TX, discusses the role of autologous stem cell transplantation (autoSCT) as a salvage therapy in Hodgkin lymphoma (HL), highlighting how autoSCT is often required for consolidation after highly intensive chemotherapy. Prof. Almeida Ramos comments on the uncertain future of autoSCT, as novel approaches such as CAR-T therapy are emerging. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: Novartis, Genentech, CRISPR Therapeutics
Research funding: Tessa Therapeutics, Athenex Therapeutics
Other remuneration: Royalties: Tessa Therapeutics
